# ABS-101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abs-101

> ABS-101, sponsored by Absci Corp (ABSI): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ABS-101 |
| Codes | ABS-101 |
| Sponsor | Absci Corp (ABSI) https://sec-api.dev/companies/absi/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001628280-24-046862): "In February 2024, we initiated IND-enabling studies and expect to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, subject to clearance of an IND or equivalent regulatory filing." https://www.sec.gov/Archives/edgar/data/1672688/000162828024046862/absi-20240930.htm

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-12, last confirmed 2025-03-18.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-013455): "Absci plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, with an interim data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-24-046856): "Absci continues to advance ABS-101 through IND-enabling studies, plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, and continues to expect an interim data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/exhibit991-2024q310xqpr.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-12, last confirmed 2025-08-12.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-013455): "Absci plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, with an interim data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-24-046856): "Absci continues to advance ABS-101 through IND-enabling studies, plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, and continues to expect an interim data readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/exhibit991-2024q310xqpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-039878): "The Phase 1 interim data readout is expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/exhibit991-2025q210xqpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-025075): "The Phase 1 interim data readout is expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/exhibit991-2025q110xqpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-039878): "•Continuing to advance all internal asset programs, with Phase 1 interim readout for ABS-101 (anti-TL1A) anticipated later this year and potential Phase 1/2a interim efficacy readout for ABS-201 (anti-PRLR) anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/exhibit991-2025q210xqpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-025075): "Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025" https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/exhibit991-2025q110xqpr.htm
- SEC Form 10-K (accession 0001628280-25-013464): "Preclinical development of ABS-101 is ongoing in preparation for a potential regulatory filing in the first half of 2025, and an anticipated interim clinical readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025013464/absi-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-025075): "Absci expects to report interim data from the ongoing study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/exhibit991-2025q110xqpr.htm
- SEC Form 10-Q (accession 0001628280-25-039938): "We anticipate an interim clinical readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025039938/absi-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-025077): "We anticipate an interim clinical readout in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1672688/000162828025025077/absi-20250331.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abs-101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABS-101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abs-101

```bibtex
@misc{secapidev_pdufa_abs_101_20261116,
  title        = {ABS-101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abs-101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abs_101_20261116","title":"ABS-101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abs-101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
